卡托普利通过缓解氧化应激改善心肌炎患儿心泵功能的临床研究  

Clinical Study of Captopril Improving Cardiac Pump Function in Children with Myocarditis by Alleviating Oxidative Stress

作　　者：代慧琳 赵楠 周羽 DAI Hui-lin;ZHAO Nan;ZHOU Yu(Department of Cardiology,Kaifeng Children's Hospital,Kaifeng 475000,Henan Province,China)

机构地区：[1]开封市儿童医院心内科,河南开封475000

出　　处：《罕少疾病杂志》2022年第12期50-52,共3页Journal of Rare and Uncommon Diseases

摘　　要：目的探究卡托普利通过缓解氧化应激改善心肌炎患儿心泵功能的临床效果。方法将符合纳入要求的120例心肌炎患儿随机分为观察组和对照组2组,每组各60例患儿,对照组和观察组分别进行常规治疗和卡托普利治疗。对比分析不同治疗方法的临床效果;同时检测血清中SOD、MDA、GST、NO、NT-proBNP以及Cys-C的水平;根据心脏彩超判断CO、CI、CR和LVEF的差异。结果观察组和对照组治疗总有效率分别为96.67%和88.33%,并且在治疗后,观察组SOD、GST、CO、CI、CR和LVEF水平显著高于对照组,MDA、NO、NT-proBNP和Cys-C水平显著差异低于对照组,差异均有统计学意义(P<0.05)。结论卡托普利可有效提高心肌炎患儿临床治疗效果,缓解氧化应激,改善心泵功能,值得临床推广使用。Objective To explore the clinical effect of captopril on improving cardiac pump function in children with myocarditis by alleviating oxidative stress.Methods 120 children with myocarditis who met the inclusion requirements were randomly divided into observation group and control group,with 60 children in each group.The control group and observation group received conventional treatment and captopril treatment respectively.The clinical effects of different treatment methods were compared and analyzed.Meanwhile,the levels of SOD,MDA,GST,NO,NT-probNP and CYS-C in serum were detected.The differences of CO,CI,CR and LVEF were determined by color doppler echocardiography.Results The total effective rate of the observation group and the control group was 96.67%and 88.33%,respectively.After treatment,SOD,GST,CO,CI,CR and LVEF levels in the observation group were significantly higher than those in the control group,MDA,NO,NT-probNP and CYS-C levels were significantly lower than those in the control group.The differences were statistically significant(P<0.05).Conclusion Captopril can effectively improve the clinical therapeutic effect of myocarditis in children,relieve oxidative stress,improve cardiac pump function,and is worthy of clinical application.

关 键 词：卡托普利 氧化应激 心肌炎患儿 心泵功能 

分 类 号：R542.21[医药卫生—心血管疾病]